Evidence map›Paper›PMID 40170546›Full record

ArticlePhysiological reports2025

Investigating the effects of rosmarinic acid on ovarian tissue, inflammatory markers, and sex hormones in polycystic ovary syndrome rats.

Sina Vakili, Farhad Koohpeyma, Mohammad Samare-Najaf, Bahia Namavar Jahromi, Morteza Jafarinia, Sepide Goharitaban, Amir Savardashtaki, Ali Samareh, Fatemeh Amini, Mohammad Hashem Hashempur

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Physiological reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07603505 (Effect of Nepeta Adenophyta Hedge Extract and Its Fractions on Polycystic Ovarian Syndrome), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07603505 phase1completednot on this map

Effect of Nepeta Adenophyta Hedge Extract and Its Fractions on Polycystic Ovarian Syndrome (PCOS)

TypeinterventionalSponsorJinnah Sindh Medical UniversityRan2025 to 2026Enrolled116ConditionsPolycystic Ovarian Syndrome (PCOS), Infertility, Metabolic DisordersArmsHerbal Formulation, Metformin XR, Metformin 750 mg and herbal formulation 500 mg
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sina VakiliInfertility Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Farhad KoohpeymaEndocrinology and Metabolism Research Center, Shiraz University of Medical Science, Shiraz, Iran.
Mohammad Samare-NajafBlood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
Bahia Namavar JahromiInfertility Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Morteza JafariniaShiraz Neuroscience Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Sepide GoharitabanDepartment of Anatomical Sciences, Faculty of Medicine, Hamedan University of Medical Sciences, Hamedan, Iran.
Amir SavardashtakiInfertility Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Ali SamarehDepartment of Clinical Biochemistry, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Fatemeh AminiDepartment of Persian Medicine and Pharmacy, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Mohammad Hashem HashempurResearch Center for Traditional Medicine and History of Medicine, Department of Persian Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0000-0002-6700-9304

Funding

Shiraz University of Medical Sciences (SUMS) 29755
6 · The paper itself

Abstract

Polycystic ovary syndrome (PCOS) causes the impairment of female fertility and elevates the risk of metabolic disorders. The current study aimed to evaluate the effects of rosmarinic acid (Ros) on the ovarian histo-stereology, the level of reproductive hormones, and inflammation in a rat model of PCOS. Fifteen adult Sprague Dawley rats were randomly divided into three groups, including controls, PCOS, and PCOS+Ros (receiving 25 mg/kg of Ros for 39 days). After treatments, the ovarian histo-stereology, the level of reproductive hormones, and the level of inflammatory markers were analyzed. PCOS led to increased ovarian weight and volume, cortical and medullary expansion, reduced ovarian follicles, and enhanced follicular atresia. It also caused hormonal imbalances, elevating LH, FSH, and testosterone while decreasing estradiol, progesterone, and AMH. Additionally, PCOS increased pro-inflammatory markers (TNF-α and IL-6) and decreased anti-inflammatory markers (IL-4 and IL-10). However, Ros administration in PCOS animals improved ovarian structure, increased follicle numbers, reduced atresia, balanced reproductive hormones, and restored inflammatory markers (p value <0.05). The present findings may suggest Ros as a novel strategy for the management of PCOS, although further studies are necessary.

Indexed as

CinnamatesDepsidesGonadal Steroid HormonesOvaryPolycystic Ovary SyndromeAnimalsBiomarkersFemaleInflammationRatsRats, Sprague-DawleyRosmarinic AcidBiomarkersCinnamatesDepsidesGonadal Steroid HormonesRosmarinic Acidhistologyhormoneinfertilityintegrative medicinephytotherapypolycystic ovary syndromerosmarinic acid

Identifiers

PMID40170546
PMCPMC11962217

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.